TLCM
VIR icon

Twin Lakes Capital Management’s Vir Biotechnology VIR Stock Holding History

Twin Lakes Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.7K Hold
2,195
– – 0.01% 168
2025
Q4 		$13.2K Hold
2,195
– – 0.01% 183
2025
Q3 		$12.5K Hold
2,195
– – 0.01% 185
2025
Q2 		$11.1K Hold
2,195
– – 0.01% 188
2025
Q1 		$14.2K Hold
2,195
– – 0.01% 176
2024
Q4 		$16.1K Hold
2,195
– – 0.01% 183
2024
Q3 		$16.4K Hold
2,195
– – 0.01% 187
2024
Q2 		$19.5K Hold
2,195
– – 0.01% 176
2024
Q1 		$22.2K Hold
2,195
– – 0.02% 173
2023
Q4 		$22.1K Hold
2,195
– – 0.02% 169
2023
Q3 		$20.6K Hold
2,195
– – 0.02% 174
2023
Q2 		$53.8K Hold
2,195
– – 0.04% 134
2023
Q1 		$51.1K Hold
2,195
– – 0.04% 133
2022
Q4 		$55.6K Hold
2,195
– – 0.04% 131
2022
Q3 		$42K Buy
+2,195
New +$55.8K 0.03% 147
2022
Q2 		– Sell
-2,195
Closed -$56K – 281
2022
Q1 		$56K Hold
2,195
– – 0.03% 151
2021
Q4 		$92K Hold
2,195
– – 0.05% 124
2021
Q3 		$96K Hold
2,195
– – 0.06% 114
2021
Q2 		$104K Buy
+2,195
New +$99.8K 0.06% 98

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Twin Lakes Capital Management's VIR Position: Q1 2026 in Review

Twin Lakes Capital Management held its Vir Biotechnology (VIR) position steady in Q1 2026 at 2,195 shares worth $19.7K. The position accounts for 0.01% of the portfolio, ranked #168.

Twin Lakes Capital Management first reported a position in VIR in Q2 2021 and has held it in 19 quarters since. The position peaked at $104K in Q2 2021. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Twin Lakes Capital Management held 2,195 shares of Vir Biotechnology worth $19.7K as of Q1 2026.
  • Twin Lakes Capital Management left its Vir Biotechnology share count unchanged in Q1 2026.
  • Vir Biotechnology made up 0.01% of Twin Lakes Capital Management's portfolio in Q1 2026, its #168 holding.
  • Twin Lakes Capital Management first reported a position in Vir Biotechnology in Q2 2021 and has held it in 19 quarters since.
  • Twin Lakes Capital Management's Vir Biotechnology position peaked at $104K in Q2 2021.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Twin Lakes Capital Management's 13F filing for Q1 2026, filed 18 May 2026.